It’s only fair to share… AZD 8931, Sapitinib, SAPATINIB PHASE 2, at AstraZeneca for the treatment of non-small cell lung cancer. CAS 848942-61-0, MF C23H25ClFN5O3, MW 473.9, pan-EGFR/pan-erbB inhibitor 4-[[4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-methyl-1-piperidineacetamide 4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl] oxy]quinazoline 4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy]quinazoline 2-[4-[4-(3-Chloro-2-fluoro-anilino)-7-methoxy-quinazolin-6-yl]oxy-1-piperidyl]-N-methyl-acetamide AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling. WO 2005028469 Inventors Robert Hugh Bradbury, Laurent Francois Andre Hennequin, …